Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
37
BTAI Quote, Financials, Valuation and Earnings
Last price:
$1.90
Seasonality move
:
3.43%
Day range:
$1.91 - $2.09
52-week range:
$1.29 - $42.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.23x
P/B ratio:
--
Volume:
95.8K
Avg. volume:
295K
1-year change:
-95.18%
Market cap:
$10.9M
Revenue:
$2.3M
EPS (TTM):
-$2.16
Analysts' Opinion
-
Consensus RatingBioXcel Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $48.00, BioXcel Therapeutics has an estimated upside of 1721.61% from its current price of $1.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $1.99.
Fair Value
-
According to the consensus of 2 analysts, BioXcel Therapeutics has 1721.61% upside to fair value with a price target of $48.00 per share.
BTAI vs. S&P 500
-
Over the past 5 trading days, BioXcel Therapeutics has overperformed the S&P 500 by 16.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioXcel Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioXcel Therapeutics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter BioXcel Therapeutics reported revenues of $214K.
Earnings Growth
-
BioXcel Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BioXcel Therapeutics reported earnings per share of -$0.32.
Enterprise value:
83.5M
EV / Invested capital:
--
Price / LTM sales:
2.23x
EV / EBIT:
--
EV / Revenue:
36.86x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$250K
Return On Assets:
-95.73%
Net Income Margin (TTM):
-3119.33%
Return On Equity:
--
Return On Invested Capital:
-197.92%
Operating Margin:
-6420.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $1.4M | $2.3M | $376K | $366K | |
| Gross Profit | $355K | $119K | $122K | -$338K | -$466K | |
| Operating Income | -$159.7M | -$167.6M | -$64.8M | -$19.9M | -$10.5M | |
| EBITDA | -$157.2M | -$165.4M | -$44.2M | -$18.7M | -$6.8M | |
| Diluted EPS | -$94.56 | -$98.40 | -$25.97 | -$12.16 | -$3.57 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $217.1M | $236.8M | $202.9M | $72.1M | $37.4M | |
| Total Assets | $219.9M | $239.4M | $205.9M | $73.7M | $38.3M | |
| Current Liabilities | $11.8M | $16.7M | $32.9M | $27.3M | $22.2M | |
| Total Liabilities | $13.2M | $17.8M | $129.1M | $130.2M | $131.4M | |
| Total Equity | $206.7M | $221.7M | $76.8M | -$56.5M | -$93.1M | |
| Total Debt | -- | -- | $93.1M | $100.6M | $102.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$135.3M | -$155M | -$72M | -$26.9M | -$14.8M | |
| Cash From Investing | -$139K | -$20K | -- | -- | -- | |
| Cash From Financing | $96.2M | $26.5M | $36.7M | $2.1M | $4.3M | |
| Free Cash Flow | -$135.5M | -$155M | -$72M | -$26.9M | -$14.8M | |
BTAI
Sector
Market Cap
$10.9M
$34.9M
Price % of 52-Week High
4.66%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
-141.23%
-0.82%
1-Year Price Total Return
-95.18%
-38.5%
Beta (5-Year)
0.640
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.81
200-day SMA
Sell
Level
$7.56
Bollinger Bands (100)
Sell
Level
1.84 - 5.84
Chaikin Money Flow
Sell
Level
-111M
20-day SMA
Buy
Level
$1.78
Relative Strength Index (RSI14)
Buy
Level
50.53
ADX Line
Buy
Level
15.01
Williams %R
Sell
Level
-13.6986
50-day SMA
Sell
Level
$2.13
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
260.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-26.9529)
Sell
CA Score
(Annual)
Level (-12.4551)
Sell
Beneish M-Score
(Annual)
Level (0.2182)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (23.5197)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Stock Forecast FAQ
In the current month, BTAI has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BTAI average analyst price target in the past 3 months is $48.00.
-
Where Will BioXcel Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioXcel Therapeutics share price will rise to $48.00 per share over the next 12 months.
-
What Do Analysts Say About BioXcel Therapeutics?
Analysts are divided on their view about BioXcel Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioXcel Therapeutics is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is BioXcel Therapeutics's Price Target?
The price target for BioXcel Therapeutics over the next 1-year time period is forecast to be $48.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is BTAI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioXcel Therapeutics is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of BTAI?
You can purchase shares of BioXcel Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioXcel Therapeutics shares.
-
What Is The BioXcel Therapeutics Share Price Today?
BioXcel Therapeutics was last trading at $1.90 per share. This represents the most recent stock quote for BioXcel Therapeutics. Yesterday, BioXcel Therapeutics closed at $1.99 per share.
-
How To Buy BioXcel Therapeutics Stock Online?
In order to purchase BioXcel Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 6.65% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 2.41% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 5.73% over the past day.
